2016-07-01
IBD: exposure to anti-TNF agents in utero: controlling health risks
Publication
Publication
Nature Reviews Gastroenterology and Hepatology , Volume 13 - Issue 7 p. 387- 388
A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.
| Additional Metadata | |
|---|---|
| , , , | |
| doi.org/10.1038/nrgastro.2016.94, hdl.handle.net/1765/93321 | |
| Nature Reviews Gastroenterology and Hepatology | |
| Organisation | Department of Gastroenterology & Hepatology |
|
van der Woude, J., & Kanis, S. (2016). IBD: exposure to anti-TNF agents in utero: controlling health risks. Nature Reviews Gastroenterology and Hepatology, 13(7), 387–388. doi:10.1038/nrgastro.2016.94 |
|